We’re looking forward to participating in and hosting C-Path's annual eCOA Consortium EU meeting on October 8–9 at ICON’s Dublin office. This meeting brings together leading eCOA experts to address key industry challen...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Access and Reimbursement for Adoptive T-Cell Transfer Drugs
ICON experts inoncology and pricing & market accessshare their thoughts on offsetting payer obstacles in this Pharmaceutical Executive article.
-
Europes New Medical Device Rules
Learn how you can avoid the expected delays and extra costs in your development process underMDR and IVDR Medical Device Regulations.
-
Bringing Precision Medicine to Traumatic Brain Injury Treatment
An article reporting on ICON's contribution to a complex pan-European traumatic brain injury (TBI) research study.
-
Trending 2018: What Does the Future Hold?
Trending 2018: What Does the Future Hold?- featuring commentary from PV100 honouree Bill Byrom, on prevailing trends in the industry.
-
Building a Comprehensive Real World Evidence Strategy
ICON’s Jim Carroll outlines how a fully integrated, multidisciplinary RWE model can save time, money and effort in study development and execution, for better commercial outcomes.
-
Adaptive Clinical Trial Designs Are Innovative
Article featuring commentary from Rolf Hvelmann and Parvin Fardipour on tackling the operational challenges of adaptive trials.
-
Big Changes for EU Medical and In Vitro Diagnostic Device Regulations
In this new ACT article, Vicki Anastasi share details on how medical device manufacturers will be challenged to generate clinical data on safety, performance and any undesirable side effects under newMDR and IVDR regulations.
-
CROs and Next-Gen Drug Development
An article featuring commentary from Steve Cutler on thefuture of drug development.
-
Is There A Better Way To Value Asset Duration In Biopharma Deal-Making?
ICON’s Andy Smith discusses the role of duration in the valuation of early-stage biopharma assets in this In Vivo article.
-
Time Is Money
ICON’s Andy Smith discusses the role of duration in the valuation of early-stage biopharma assets in this In Vivo article.
